HC Wainwright & Co. Maintains Buy on Entasis Therapeutics Hldg, Raises Price Target to $6
HC Wainwright & Co. analyst Ed Arce maintains Entasis Therapeutics Hldg (NASDAQ:ETTX) with a Buy and raises the price target from $5 to $6.
18 Stocks Moving in Tuesday’s Pre-Market Session
Gainers
Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) rose 26.1% to $2.03 in pre-market trading after surging 18% on Monday. Kaival Brands Innovations recently announced plans to launch distribution of its products in the U.K.
Entasis Therapeutics Announces Topline Results From Phase 3 ATTACK Trial; SUL-DUR Met Primary Efficacy Endpoint
SUL-DUR first to achieve statistical non-inferiority in 28-day all-cause mortality in carbapenem-resistant Acinetobacter (CRAB) patients
Statistically significant difference in clinical cure at Test of Cure vs.
Entasis Therapeutics To Participate In Cantor Global Healthcare Conference Thursday, Sept. 30 At 1:20 p.m. EDT
Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that management will participate in
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 20)
Why Are Entasis Therapeutics Shares Moving Higher On Thursday?
Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) stock is up sharply after the journal Nature published an article on the potential of its…
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 11)